Published in Science Translational Medicine: Phosphoproteomics identifies hyperactive kinase targets and treatment combinations in colorectal cancer

• Post by: OPL
• September 6, 2023
• Comments off

Can mass spectrometry-based phosphoproteomics help understand the (lack of) response to EGFR-blockade and identify predictive markers and new treatment options?
We analyzed a unique collection of 29 molecularly characterized colorectal patient-derived xenograft (PDX) tumors, annotated for cetuximab response. Proteomics identified CXADR as promising marker of treatment response, while phosphoproteomics coupled to single sample kinase activity ranking pinpointed known driver kinases as well as potential novel targets in cetuximab resistant tumors that were functionally validated.
See also: here link to the CCA website
Link to website/publication:
Publication via Science Translational Medicine website: https://www.science.org/doi/10.1126/scitranslmed.abm3687